AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed that ...

London’s blue chip stocks suffered another dip on Friday as the pound added to recent gains. Some of the City’s key ...

Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...

In the commodities sector, demand for gold and other precious metals funds reached a four-and-a-half-month high as investors poured $1.41 billion into these funds. Energy funds also saw a slight ...

Global sectoral equity funds also saw a net $258 million worth of sales, the first weekly outflow in six weeks. Consumer ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.